Downregulation of thioredoxin reductase 1 expression in the substantia nigra pars compacta of Parkinson's disease mice

Neural Regeneration Research

Volumn 8, Issue 35, 2013, Pages 3275-3283

  Liu, Zi Hua ^a   Jing, Yu Hong ^a,b   Yin, Jie ^a   Mu, Ji Ying ^a   Yao, Ting Ting ^a   Gao, Li Ping ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b Key Laboratory of Preclinical Study for New Drugs of Gansu Province   (China)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Brain injury; Grants supported paper; Midbrain; Neural regeneration; Neurodegeneration; Neuroregeneration; Oxidative stress; Parkinson's disease; Substantia nigra pars compacta; Thioredoxin reductase; Tyrosine hydroxylase

Indexed keywords

MESSENGER RNA; THIOREDOXIN REDUCTASE 1; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLORIMETRY; CONTROLLED STUDY; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; MOUSE; MPTP-INDUCED PARKINSONISM; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA PARS COMPACTA; WESTERN BLOTTING; ANIMAL EXPERIMENT; ENZYME ACTIVITY; IMMUNOREACTIVITY; OXIDATIVE STRESS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY;

EID: 84892751052     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.35.002     Document Type: Article

References (58)

1. Gasser T. Mendelian forms of Parkinson's disease. Biochim Biophys Acta. 2009;1792(7):587-596.
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4): 368-376.
3. Schober A. Classic toxin-induced animal models of Parkinson's disease 6-OHDA and MPTP. Cell Tissue Res. 2004;318(1):215-224.
4. Yang JL, Chen JS, Yang YF, et al. Neuroprotection effects of retained acupuncture in neurotoxin-induced Parkinson's disease mice. Brain Behav Immun. 2011;25(7):1452-1459.
5. Maher P. Redox control of neural function: background, mechanisms, and significance. Antioxid Redox Signal. 2006;8(11-12):1941-1970.
6. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci. 2008;1147: 93-104.
7. Mounsey RB, Teismann P. Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinsons Dis. 2010;2011:617472.
8. Federico A, Cardaioli E, Da Pozzo P, et al. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci. 2012;322(1-2):254-262.
9. Miller RL, James-Kracke M, Sun GY, et al. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res. 2009;34(1):55-65.
10. Mariani E, Polidori MC, Cherubini A, et al. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827(1):65-75.
11. Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A. 1996;93(7): 2696-2701.
12. Kopalli SR, Noh SJ, Koppula S, et al. Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease. Neurotoxicology. 2012;34:25-32.
13. Muroyama A, Fujita A, Lv C, et al. Magnolol protects against MPTP/MPP(+)-induced toxicity via inhibition of oxidative stress in vivo and in vitro models of Parkinson's disease. Parkinsons Dis. 2012;2012:985157.
14. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem. 1997;69(3):1196-1203.
15. Lv Z, Jiang H, Xu H, et al. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm. 2011; 118(3):361-369.
16. Mochizuki H, Yasuda T. Iron accumulation in Parkinson's disease. J Neural Transm. 2012;119(12):1511-1514.
17. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem. 1998;70(1): 268-275.
18. Good PF, Hsu A, Werner P, et al. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol. 1998; 57(4):338-342.
19. Kunikowska G, Jenner P. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease. Brain Res. 2003;968(2): 206-218.
20. Bharath S, Hsu M, Kaur D, et al. Glutathione, iron and Parkinson's disease. Biochem Pharmacol. 2002;64(5-6): 1037-1048.
21. Ayton S, Lei P, Duce JA, et al. Ceruloplasmin dysfunction and therapeutic potential for parkinson disease. Ann Neurol. 2012.
22. Conrad M, Schick J, Angeli JP. Glutathione and thioredoxin dependent systems in neurodegenerative disease: What can be learned from reverse genetics in mice. Neurochem Int. 2013;62(5):738-749.
23. Mitchell J, Morris A, de Belleroche J. Thioredoxin reductase 1 haplotypes modify familial amyotrophic lateral sclerosis onset. Free Radic Biol Med. 2009;46(2):202-211.
24. Arnér ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000; 267(20):6102-6109.
25. Turanov AA, Kehr S, Marino SM, et al. Mammalian thioredoxin reductase 1: roles in redox homoeostasis and characterization of cellular targets. Biochem J. 2010; 430(2):285-293.
26. Mandal PK, Schneider M, Kölle P, et al. Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res. 2010; 70(22):9505-9514.
27. Soerensen J, Jakupoglu C, Beck H, et al. The role of thioredoxin reductases in brain development. PLoS One. 2008;3(3):e1813.
28. Lovell MA, Xie C, Gabbita SP, et al. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic Biol Med. 2000;28(3): 418-427.
29. Lamoke F, Ripandelli G, Webster S, et al. Loss of thioredoxin function in retinas of mice overexpressing amyloid β. Free Radic Biol Med. 2012;53(3):577-588.
30. Kudin AP, Augustynek B, Lehmann AK, et al. The contribution of thioredoxin-2 reductase and glutathione peroxidase to H(2)O(2) detoxification of rat brain mitochondria. Biochim Biophys Acta. 2012;1817(10):1901-1906.
31. Jurado J, Prieto-Alamo MJ, Madrid-Rísquez J, et al. Absolute gene expression patterns of thioredoxin and glutaredoxin redox systems in mouse. J Biol Chem. 2003; 278(46):45546-45554.
32. Ozsoy O, Seval-Celik Y, Hacioglu G, et al. The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease. Neurochem Int. 2011;59(5): 664-670.
33. Burke WJ, Kumar VB, Pandey N, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008;115(2):193-203.
34. Schmidt N, Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm. 2001; 108(11):1263-1282.
35. Fontanilla CV, Ma Z, Wei X, et al. Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. Neuroscience. 2011; 188:135-141.
36. Przedborski S, Jackson-Lewis V, Naini AB, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem. 2001;76(5):1265-1274.
37. Wang WF, Wu SL, Liou YM, et al. MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. Behav Neurosci. 2009;123(6):1261-1270.
38. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neuro-degeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A. 2001; 98(25):14669-14674.
39. Li S, Pu XP. Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. Biol Pharm Bull. 2011;34(8):1291-1296.
40. Rojo AI, Montero C, Salazar M, et al. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Eur J Neurosci. 2006;24(7):1874-1884.
41. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979-980.
42. Yokoyama H, Kuroiwa H, Yano R, et al. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci. 2008;29(5):293-301.
43. Kahles T, Brandes RP. NADPH oxidases as therapeutic targets in ischemic stroke. Cell Mol Life Sci. 2012; 69(14):2345-2363.
44. Choi DH, Cristóvão AC, Guhathakurta S, et al. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal. 2012;16(10):1033-1045.
45. Sorce S, Krause KH, Jaquet V. Targeting NOX enzymes in the central nervous system: therapeutic opportunities. Cell Mol Life Sci. 2012;69(14):2387-2407.
46. Wu DC, Teismann P, Tieu K, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A. 2003;100:6145-6150.
47. Philippens IH, Wubben JA, Finsen B, et al. Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model. J Neuroimmune Pharmacol. 2013.
48. Zhang J, Graham DG, Montine TJ, et al. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J Neuropathol Exp Neurol. 2000; 59(1):53-61.
49. Thiruchelvam M, Prokopenko O, Cory-Slechta DA, et al. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype. J Biol Chem. 2005;280(23):22530-22539.
50. Tamura T, Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci U S A. 1996;93(3):1006-1011.
51. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem. 1989;264(24):13963-13966.
52. Wipf P, Lynch SM, Birmingham A, et al. Natural product based inhibitors of the thioredoxin-thioredoxin reductase system. Org Biomol Chem. 2004;2(11):1651-1658.
53. Seyfried J, Wüllner U. Inhibition of thioredoxin reductase induces apoptosis in neuronal cell lines: role of glutathione and the MKK4/JNK pathway. Biochem Biophys Res Commun. 2007;359(3):759-764.
54. Peng Y, Feng SF, Wang Q, et al. Hyperbaric oxygen preconditioning ameliorates anxiety-like behavior and cognitive impairments via upregulation of thioredoxin reductases in stressed rats. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):1018-1025.
55. Vauzour D, Buonfiglio M, Corona G, et al. Sulforaphane protects cortical neurons against 5-S-cysteinyl-dopamine-induced toxicity through the activation of ERK1/2, Nrf-2 and the upregulation of detoxification enzymes. Mol Nutr Food Res. 2010;54(4):532-542.
56. Lopert P, Day BJ, Patel M. Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cells. PLoS One. 2012;7(11):e50683.
57. The Ministry of Science and Technology of the people's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animal. 2006-09-30.
58. Yokoyama H, Takagi S, Watanabe Y, et al. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J Neural Transm. 2008;115(6): 831-842.